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Background: Tumours of the gastrointestinal (GI) tract, share a major burden for mortality and morbidity all over 
the world. The most common site of carcinoma of GIT is colon and rectum (70%). The etiological factors may be 
environmental (diet) and genetic. CDX-2 has been proposed as being present in most of the cases with colorectal 
carcinoma. To determine the frequency of positive expression of CDX2 in diagnosed cases of colorectal 
adenocarcinoma diagnosed on haematoxylin and eosin stain. 
Methods: This was a cross-sectional study and was conducted at Histopathology department, Federal 
Government Polyclinic, PGMI, Islamabad over period of 2 years we included all paraffin embedded tissue 
sections of colorectal carcinoma of both genders with an age range of 25-75 years. Specimens were stained with 
Heamatoxylin and Eosin (H & E) and examined microscopically for presence or absence of invasive cancer. 
Another specimen was taken and stained with CDX2. The data were analyzed using SPSS version 24. 
Results: A total of 125 cases with colorectal carcinoma diagnosed on H & E stain were included in the study. The 
mean age of the patients was found to be 52.66 ± 14.62 years. In this study, 67 patients (53.6%) were male and 58 
patients (46.4%) were having final diagnosis of Adenocarcinoma. Regarding the site, most common lesion 
involved rectum, followed by sigmoid colon and ascending colon. Among 125 specimens reviewed, 112 patients 
(89.6%) were CDX-2 positive while 13 patients (10.4%) were CDX-2 negative. Also we stratified the CDX-2 
expression according to site and type of colorectal carcinoma and was found significant for both of these (P<0.05). 
Conclusion: We concluded that CDX-2 was present in almost 90% of colorectal carcinoma specimens so it can be 
used as an important diagnostic tool for colorectal carcinoma during histopathological diagnosis.  





Colorectal carcinoma is one of the most frequent 
carcinomas and hold 3rd position in terms of frequency 
following breast and lung. It was also reported as the 
second most common cause of the cancer death (10%) 
after lung cancer in the UK in 2006 1, 2. 
Immunohistochemistry has been used for many 
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decades for definitive diagnosis of colorectal cancer. 
Different immune his to chemical markers have been 
used so far. The most popular among them is CK20. It 
is a low molecular weight keratin, which is most 
commonly expressed in the gastrointestinal 
epithelium, urothelium and Merkel cells. The CK7 –
/CK20 + expression pattern is known to be highly 
characteristic of colorectal Adenocarcinoma3. However 
not all the colorectal Adenocarcinomas show this 
pattern? Therefore, there is a continuous need for 
more sensitive markers for intestinal epithelium and 
CDX2 appears to be a better marker than those 
existing before(4). 
CDX2 is a nuclear homeobox transcription factor that 
belongs to the caudal – related family of CDX 
homeobox genes. It is involved in the process of 
intestinal epithelial proliferation, differentiation, 
adhesion and apoptosis. It is normally expressed 
within the nuclei of epithelial cells of GIT starting 
from duodenum to the rectum. Recent 
histopathological studies have shown CDX2 to be a 
sensitive and specific marker for adenocarcinoma of 
the GIT, particularly those found in colon and rectum 
5. Its expression is reported to be as high as 97% of 
specimens3, while some studies have shown loss of its 
expression in 14-37% of specimens, probably due to 
high tumour grade, microsatellite instability or 
advanced tumour stage5, 6.   
Immunohistochemistry using CDX2 is a reliable and 
quick method of detecting colorectal carcinoma 7, 8. 
The objective of the study was to determine the 
frequency of positive expression of CDX2 in 
diagnosed cases of colorectal adenocarcinoma 
diagnosed on haematoxylin and eosin stain. 
 
Patients and Methods 
This study was conducted at Histopathology 
department, Federal Government Polyclinic, PGMI, 
Islamabad. It was a cross-sectional study and the 
duration was 2 years, from January 2017 to December 
2018. We included all paraffin embedded tissue 
sections of colorectal carcinoma of both genders with 
an age range of 25-75 years. Our exclusion criteria 
included endoscopic biopsies, autolyzed biopsies, 
tissues without proper formalin fixation, resections 
after pre-surgical neoadjuvant therapy and tissue 
blocks containing extensive necrosis and hemorrhage. 
SAMPLE SIZE of 125 cases was calculated according 
to WHO sample size calculator taking confidence 
Level of 95%, anticipated population proportion as 
97% and absolute precision as 03%. Sampling 
technique used was non-probability consecutive 
sampling. The criteria set for positivity of CDX2 were 
staining of at least 50% of tumour cells by CDX2. 
Freshly cut 3-5 microns thick sections stained with 
Heamatoxylin and Eosin (H & E) were examined 
microscopically by consultant histopathologist. The 
presence/absence of invasive cancer was reported. 
Another 3-5 microns thick section of the original 
tumour, stained with CDX2 was looked again for the 
uptake of stain by cancer cells by the same 
histopathologist and reported. The data was analyzed 
using SPSS version 24. Frequency was calculated for 
qualitative variables like positive expression of CDX2, 
gender and types of colorectal adenocarcinoma. Mean 
was calculated for quantitative variables like age of the 
patients. Effect modifiers like age and gender were 
controlled by stratification. Post stratification chi-
square test was applied, and p-value ≤0.05 was 
considered as significant. 
                                            
Result 
A total of 125 cases with colorectal carcinoma 
diagnosed on H & E stain were included in the study. 
The mean age of the patients was found to be 52.66 ± 
14.62 years. In this study, 67 patients (53.6%) were 
male and 58 patients (46.4%) were having final 
diagnosis of Adenocarcinoma. Regarding the site, 
most common lesion involved rectum, followed by 
sigmoid colon, ascending colon, transverse colon and 
descending colon (table 1).  
 
Table No. 1: Distribution of the patients according to 
site involved 
Age  
(mean ± SD) 









 Ascending Colon 
 Transverse Colon 
 Descending Colon 
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Type of colorectal carcinoma (n(%) 
Adenocarcinoma 
 Mucinous Carcinoma 




 Table 2: Stratification of CDX-2 expression for site and 
type of carcinoma 
 CDX-2 Total 
Positive Negative 
Site of Colon    
Ascending Colon 19 2 21 
Transverse Colon 8 3 11 
Descending Colon 5 3 8 
Sigmoid Colon 29 2 31 
Rectum 51 3 54 
Total 112 13 125 
P = 0.001 
Type of Colorectal Carcinoma 
Adenocarcinoma 95 7 102 
Mucinous 
Carcinoma 
12 4 16 
Signet ring cell 
carcinoma 
5 2 7 
Total 112 13 125 
P Value= 0.023 
 
 
Figure 1. High power view (x400X) of colorectal 
adenocarcinoma with atypical glands lined by 
pleomorphic cells having hyperchromatic nuclei, 




Figure 2. Low power view (x100X) of colorectal 
adenocarcinoma exhibiting nuclear positivity for 
CDX2 immunohistochemical marker 
Among 125 specimens reviewed, 112 patients (89.6%) 
were CDX-2 positive while 13 patients (10.4%) were 
CDX-2 negative. Also we stratified the CDX-2 
expression according to site and type of colorectal 
carcinoma and was found significant for both of these 
(P<0.05) (table 2) 
  
Discussion 
Colon and rectum are the most common place for 
carcinoma of GIT and it is related to higher morbidity 
and mortality. Its incidence is higher in older age and 
more than 90% of cases are found in individuals with 
age being higher than 55 years 9. In this study, the 
mean age of the patients was found to be 52.66 ± 14.62 
years which is comparable to previous literature 10, 11. 
In this study, 67 patients (53.6%) were male while 58 
patients (46.4 %) were females. In contrary to some 
foreign studies who have reported more 
preponderance of colorectal carcinomas in males (male 
vs. female 2:1), we found almost an equal distribution 
among both gender (12). However, as there is no central 
registry program for carcinomas in our country, 
therefore exact incidence and gender variation is not 
known in our population. In another large study from 
Pakistan, gender distribution was equal in both 
genders for colonic carcinomas (1:1), higher in males 
for rectal carcinomas (2:1) and higher for males in 
cases of total colorectal carcinomas (1.7:1) 13. 
The distribution of colorectal carcinoma according to 
site was also assessed in this study. We found that 
most common site of carcinoma was rectum and left 
colon. Classically, most commonly left sided colon is 
considered frequent site for carcinoma. However, 
some recent studies have reported higher incidence for 
of right colon in many parts of the world (14). In this 
study, only small number (16.8%) of the patients had 
right-sided or proximal colon cancer. Amanda IP and 
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colleagues surveyed a large number of patients with 
colorectal carcinoma and they found almost similar 
results. In their study most common location of 
colorectal carcinoma was found to be rectum, similar 
to our study 15. 
Human CDX2 protein is a member of the homeobox 
genes that is found in the nuclei of epithelium of GIT 
both in fetal life and after birth. In addition, CDX2 
mRNA expression is found only in gastrointestinal 
tract epithelium cells. The accuracy of CDX-2 
expression among patients with colorectal carcinoma 
is reported to be greater than 90% (5). Werling et al 
conducted a study and included 476 specimens and 
found it to be an excellent marker of adenocarcinomas 
of GIT, particularly for those arising from duodenum 
and colon. They found higher levels (>75% positive 
cells) of CDX2 expression in colorectal 
adenocarcinomas, while intermediate levels (26%-75% 
positive cells) of expression in adenocarcinomas 
arising elsewhere in the intestine. They also found that 
similar levels of expression of CDX2 staining are 
shown by primary and metastatic colorectal 
carcinomas. All primary and metastatic colonic 
adenocarcinomas (except one specimen in metastatic 
group) showed higher levels of CDX2 expression (2+ 
or 3+) 16. Similar to it, in another study, authors 
reported CDX2 expression in all colorectal metastatic 
specimens 17.  
In this study, CDX-2 expression was found positive in 
112 of 125 (89.6%) cases, which is consistent with the 
previous studies reported. To the best of my 
knowledge, it is the only study conducted which has 
revealed the frequency of CDX-2 expression in 
patients with colorectal carcinoma in our population 
and no study has been done previously on this topic. I 
hope that this study will help us making diagnosis of 
colorectal cancer easier and will help us making 
patient management better. However, more work and 
research is needed to explore other aspects of the 
disease and CDX-2 association. 
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